25 Years' experience with lymphangiomas in children

Alqahtani, Aayed R.; Nguyen, L.T.; Flageole, Hélène; Shaw, Kenneth; Laberge, Jean-Martin

doi:10.1016/s0022-3468(99)90590-0

Cited by 372 publications

(310 citation statements)

References 11 publications

Supporting

Mentioning

270

Contrasting

Unclassified

Order By: Relevance

“…In this study, the most prevalent lesion sites were head, neck, and lower extremity, which was concordant with a previous report (18). In the literature, the prevalent age of LM was reported as infancy and young childhood (80-90% before the age of 2 years) (18).…”

Section: Discussionsupporting

confidence: 92%

Infusion Sclerotherapy of Microcystic Lymphatic Malformation: Clinico-Radiological Mid-Term Results

Lee

Chung

et al. 2016

J Korean Soc Radiol

View full text Add to dashboard Cite

Purpose:A new sclerotherapy technique by slow mechanical infusion of sclerosant was validated for treatment of microcystic lymphatic malformation (mLM). Materials and Methods: Seventeen consecutive patients with mLM in extremities, cervicofacial area, and trunk were included (21.8 ± 21.5 years old, male:female = 5:12). All patients diagnosed as mLM were included. A total 4-32 mL 20-38% OK-432 solution was mechanically infused at the rate of 10 mL/hour into the mLM lesions. The treatment effect was estimated clinic-radiologically at the 4-month follow-up. Repeated sclerotherapy followed in the 6th month, if required. The therapeutic effect was evaluated using quantitative ultrasonographic examination including soft tissue thickness, cyst size and number. Results: In 17 patients, total 31 infusion sclerotherapy sessions were performed and monitored for 425 ± 266 days. Fifteen patients (88%) showed improvement in all symptoms, signs, and ultrasonographic findings. In all cases, at least one finding presented improvement. The maximal number of cysts per ultrasonographic window and maximal diameter of the largest cyst decreased by 57 ± 57% and 51 ± 67%, respectively (p = 0.102, 0.004). The soft tissue thickness decreased by 18 ± 15% (p < 0.01). No significant complications such as distal lymphedema or skin necrosis occurred. Conclusion: Infusion sclerotherapy is a safe and effective treatment technique for microcystic LM, with improved outcome.

show abstract

Section: Discussionsupporting

confidence: 92%

Infusion Sclerotherapy of Microcystic Lymphatic Malformation: Clinico-Radiological Mid-Term Results

Lee

Chung

et al. 2016

J Korean Soc Radiol

View full text Add to dashboard Cite

show abstract

“…The origin of this tumor is thought to be either trauma or an anomaly of the lymphatic system. [1][2][3][4][5][6][7] This embryonal theory is supported by the fact that most cases are diagnosed during childhood. Other possible etiologies include bleeding or inflammation in the lymphatic channels, both leading to obstruction and subsequent lymphangioma formation.…”

Section: Discussionmentioning

confidence: 97%

Cystic lymphangioma of small bowel mesentery: a rare case report

2015

View full text Add to dashboard Cite

“…They can be used as a therapeutic weapon against lymphangiomas, especially in patients with unresectable or lifethreatening lesions or in cases in which surgery would be mutilating. Spontaneous regression of mediastinal lymphangioma has been seen, although it remains uncommon [20]. Among sclerotizing agents, OK-432 (Picibanil), a lyophilized mixture of Su-protein of group A Streptococcus pyogenes, incubated with penicillin G, had a response rate up to 92% with minimal side effects and no cicatricial damage to the skin [21].…”

Section: Discussionmentioning

confidence: 99%